Abstract:While it is now accepted that the gut microbiota contribute to the genotype-environment-lifestyle interactions triggering inflammatory bowel disease (IBD) episodes, efforts to identify the pathogen(s) that cause these diseases have met with limited success. The advent of culture-independent techniques for characterizing the structure and/or function of microbial communities (hereafter referred to as metagenomics) has provided new insights into the events associated with the onset, remission and recurrence of IBD. A large number of observational and/or case-control studies of IBD patients have confirmed substantive changes in gut bacterial profiles (dysbiosis) associated with disease. These types of studies have been augmented by new profiling approaches that support the identification of more ‘colitogenic' bacteria from numerically predominant taxa. Evidence of alterations in lesser abundant taxa such as the methanogenic archaea, to favor types that are more immunogenic, has also been forthcoming. Several recent longitudinal studies of patients with Crohn's disease have produced additional insights, including evidence for the role of ‘anti-inflammatory' microbiota in providing a protective effect and/or promoting remission. In summation, the implications of dysbiosis and restoration of a ‘healthy microbiota' in IBD patients requires definition beyond a taxonomic assessment of the changes in the gut microbiota during disease course. The available evidence does suggest that specific members of the gut microbiota can contribute either pro- or anti-inflammatory effects, and their ecological fitness in the large bowel affects the onset and recurrence of IBD. While metagenomics and related approaches offer the potential to provide novel and important insights into these microbiota and thereby the pathophysiology of IBD, we also need to better understand factors affecting the ecological fitness of these microbes, if new treatment of IBD patients are to be delivered.

Fatty acids produced by the gut microbiota dampen host inflammatory responses by modulating intestinal SUMOylation

dampens SUMOylation and promotes intestinal inflammation

Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis

A major mechanism for immunomodulation: Dietary fibres and acid metabolites

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Fecal let-7b and miR-21 directly modulate the intestinal microbiota, driving chronic inflammation

The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective

Regulation of immune cell function by short-chain fatty acids

Gut microbial fatty acid isomerization modulates intraepithelial T cells

Regulation of inflammation by short chain fatty acids

From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites

Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections

Regulation of short-chain fatty acids in the immune system

Gut bacterial metabolites modulate endoplasmic reticulum stress

Human gut commensal modulates the host lipidome and delivers anti-inflammatory outer membrane vesicles to suppress colitis in an -deficient mouse model

Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases

A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules

Bacterial short‐chain fatty acid metabolites modulate the inflammatory response against infectious bacteria

Inhibition of inflammatory microglia by dietary fiber and short-chain fatty acids

The effect of microbial metabolites from colonic protein fermentation on bacteria-induced cytokine production in dendritic cells

Are Short Chain Fatty Acids in Gut Microbiota Defensive Players for Inflammation and Atherosclerosis?